(Article 223-16 of General Regulation of the French financial markets authority)
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: Euronext Growth
ISIN code: FR0010425595
Date | Total number of shares in the capital | Total number of voting | ||
10/31/2018 | 42,430,026 | 47,447,512 |
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing built on its flagship TALEN technology and pioneering electroporation system PulseAgile Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark owned by the Cellectis Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005188/en/
Contacts:
Media:
Jennifer Moore
VP of Communications
917-580-1088
media@cellectis.com
Caitlin Kasunich
KCSA Strategic Communications
212-896-1241
ckasunich@kcsa.com
IR:
Simon Harnest
VP of Corporate Strategy and Finance
646-385-9008
simon.harnest@cellectis.com